<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008904</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-12062</org_study_id>
    <secondary_id>HM12062</secondary_id>
    <secondary_id>CDR0000650938</secondary_id>
    <secondary_id>NCI-2012-01059</secondary_id>
    <nct_id>NCT01008904</nct_id>
  </id_info>
  <brief_title>Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer</brief_title>
  <official_title>A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Magnesium oxide may help relieve hot flashes in women with cancer.

      PURPOSE: This phase II trial is studying how well magnesium oxide works in treating hot
      flashes in menopausal women with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if magnesium oxide supplement will decrease the frequency and severity of
           hot flashes by 50% in menopausal women with cancer.

      Secondary

        -  To evaluate the effect of magnesium oxide on overall quality of life.

        -  To evaluate the toxicities of magnesium oxide when administered at commonly used
           supplement doses.

      OUTLINE: Patients receive oral magnesium oxide once daily in weeks 2-5. Patients whose hot
      flashes are not satisfactorily controlled after 2 weeks of treatment may receive magnesium
      oxide twice daily in weeks 4 and 5.

      Patients complete a daily hot flash diary for 5 weeks beginning 1 week before treatment.
      Patients also complete quality-of-life, symptom, and self-assessment questionnaires at
      baseline, once weekly during treatment, and at the completion of treatment.

      After completion of study treatment, patients are followed up for at least 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5)</measure>
    <time_frame>from baseline to week 5</time_frame>
    <description>Hot flash score (frequency x severity) at baseline was compared to the end of treatment. The number of flashes in a 24 hour day and a score combining the number and severity of hot flashes (ie, 1 point for mild, 2 points for moderate, 3 points for severe and 4 points for very severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life</measure>
    <time_frame>from baseline to week 5</time_frame>
    <description>Mayo Clinic Uniscale instrument (6 questions with each question rating 0=as bad as it can be and 10=as good as it can be). A lower score is considered to be a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer Survivor</condition>
  <condition>Hot Flashes</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Supportive care (magnesium oxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium oxide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (magnesium oxide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (magnesium oxide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (magnesium oxide)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  History of breast cancer (currently without malignant disease)

               -  No history of breast cancer but wishes to avoid estrogen due to a perceived
                  increased risk of breast cancer

          -  Must have bothersome hot flashes (defined by their occurrence of ≥ 14 times per week
             and of sufficient severity to make the patient desire therapeutic intervention) for ≥
             1 month before study entry

          -  Has undergone treatment for cancer (patients other than breast cancer survivors are
             eligible)

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Creatinine clearance ≥ 30 mL/min

          -  No hypersensitivity to magnesium oxide

          -  No medical or other condition(s) that, in the opinion of the
             investigator/sub-investigator, may compromise the objectives of the study

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior and no concurrent antineoplastic chemotherapy,
             androgens, estrogens, progestational agents, or gabapentin

          -  More than 28 days since prior and no other concurrent investigational drugs

          -  Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed provided patient has
             been on a constant dose for &gt; 4 weeks AND is not expected to stop the medication
             during the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Park H, Parker GL, Boardman CH, Morris MM, Smith TJ. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer. 2011 Jun;19(6):859-63. doi: 10.1007/s00520-011-1099-7. Epub 2011 Jan 27.</citation>
    <PMID>21271347</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <results_first_submitted>August 12, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2014</results_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer survivor</keyword>
  <keyword>hot flashes</keyword>
  <keyword>breast cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled female patients with bothersome hot flashes (defined by their occurrence ≥14 times per week and of sufficient severity to make the patient desire therapeutic intervention for ≥ 1 month prior to study entry) after undergoing treatment for cancer. Patients were recruited from the Massey Cancer Center oncology clinics.</recruitment_details>
      <pre_assignment_details>Of the 31 patients enrolled, 29 received treatment. 25 completed treatment and were analyzed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Supportive Care (Magnesium Oxide)</title>
          <description>Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unexpected unrelated surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patient who started study treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Supportive Care (Magnesium Oxide)</title>
          <description>Patients receive magnesium oxide PO QD or BID for 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5)</title>
        <description>Hot flash score (frequency x severity) at baseline was compared to the end of treatment. The number of flashes in a 24 hour day and a score combining the number and severity of hot flashes (ie, 1 point for mild, 2 points for moderate, 3 points for severe and 4 points for very severe.</description>
        <time_frame>from baseline to week 5</time_frame>
        <population>25 patients completed the complete study and were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Magnesium Oxide)</title>
            <description>Patients receive magnesium oxide PO QD or BID for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5)</title>
          <description>Hot flash score (frequency x severity) at baseline was compared to the end of treatment. The number of flashes in a 24 hour day and a score combining the number and severity of hot flashes (ie, 1 point for mild, 2 points for moderate, 3 points for severe and 4 points for very severe.</description>
          <population>25 patients completed the complete study and were analyzed</population>
          <units>percentage of difference</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.4" spread="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Quality of Life</title>
        <description>Mayo Clinic Uniscale instrument (6 questions with each question rating 0=as bad as it can be and 10=as good as it can be). A lower score is considered to be a better outcome.</description>
        <time_frame>from baseline to week 5</time_frame>
        <population>Participants who completed treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Magnesium Oxide)</title>
            <description>Patients receive magnesium oxide PO QD or BID for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Quality of Life</title>
          <description>Mayo Clinic Uniscale instrument (6 questions with each question rating 0=as bad as it can be and 10=as good as it can be). A lower score is considered to be a better outcome.</description>
          <population>Participants who completed treatment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study start to study completion. (5 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Supportive Care (Magnesium Oxide)</title>
          <description>Patients receive magnesium oxide PO QD or BID for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <description>unrelated due to seroma involving the left breast flap, after bilateral TRAM flap</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas J. Smith, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>410-955-2091</phone>
      <email>tsmit136@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

